Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company with a market capitalization of $906 million, sold 4,304 shares of common stock on July 30, 2025. According to InvestingPro data, the company’s stock has shown significant volatility, trading between $8.18 and $29.56 over the past 52 weeks. The shares were sold at a weighted average price of $12.011, for a total value of $51,695. The price per share ranged from $11.78 to $12.315.
On the same day, van Houte also acquired a total of 11,494 shares of Nurix Therapeutics common stock through the exercise of restricted stock units. These transactions did not involve any payment per share.
In other recent news, Nurix Therapeutics has caught the attention of several major investment firms with their latest developments. Following the company’s second-quarter financial results, Morgan Stanley (NYSE:MS) adjusted its price target for Nurix to $16, citing increased spending for upcoming pivotal trials. UBS also lowered its price target to $26, noting heightened operational expenses, while maintaining a Buy rating. Meanwhile, Goldman Sachs has initiated coverage on Nurix with a Buy rating and a notably higher price target of $182, driven by expectations for the Crenessity drug launch. Stifel reiterated its Buy rating and $35 price target, projecting potential peak sales exceeding $4.5 billion for Nurix’s lead drug candidate. The firm anticipates that Nurix will announce registrational development plans for bexobrutideg in the latter half of 2025. These insights reflect a mix of optimism and caution among analysts regarding Nurix’s financial and strategic outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.